Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis

We evaluated the cost-utility of replacing trivalent influenza vaccine (TIV) with quadrivalent influenza vaccine (QIV) in the current target populations in Uruguay. An existing decision-analytic static cost-effectiveness model was adapted for Uruguay. The population was stratified into age groups. C...

Descripción completa

Detalles Bibliográficos
Autores principales: Bianculli, Pablo Manuel, Bellier, Lucile, Mangado, Ignacio Olivera, Pérez, Carlos Grau, Mieres, Gustavo, Lazarov, Luis, Petitjean, Audrey, Dibarboure, Hugo, Lopez, Juan Guillermo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Influenza – Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225211/
https://www.ncbi.nlm.nih.gov/pubmed/35344679
http://dx.doi.org/10.1080/21645515.2022.2050653

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225211/
https://www.ncbi.nlm.nih.gov/pubmed/35344679
http://dx.doi.org/10.1080/21645515.2022.2050653

Ejemplares similares